肠癌的早期症状往往不典型，容易被忽视，但若能及时发现这些信号，就能抓住最佳治疗时机。 "排便习惯改变是肠癌最常见的早期信号，如排便次数增多、腹泻与便秘交替出现、有排便不尽感，以 及大便性状发生变化，出现大便变细、带血、带黏液或脓血便等。"田利军说，部分患者还会出现不明 原因的腹痛、腹胀，不明原因的体重下降、乏力、贫血等全身症状，一旦出现这些表现，需及时做肠镜 检查。 肠癌是可防、可筛、可治的肿瘤。田利军表示，一级预防以改善生活方式为主，饮食上要增加膳食纤维 的摄入，多吃蔬菜、水果、粗粮，戒烟限酒，养成规律的排便习惯。同时要坚持适度运动，控制体重， 避免久坐。积极治疗肠道慢性疾病，从根源上阻断癌变可能。二级预防的核心是早筛查。40岁以上的普 通人群，要定期做肠镜检查。有肠癌家族史、肠道疾病史的高危人群，应提前筛查年龄，并增加筛查频 率。除了肠镜，粪便隐血试验、肿瘤标志物检测等也可作为辅助筛查手段。 （来源：工人日报） 本报讯 （记者刘建林 李彦斌）春节即将到来，各种聚会增加，暴饮暴食是常见问题。近日，山西省人 民医院结直肠肛门外科主任医师田利军在接受《工人日报》记者采访时表示，目前，肠癌包括结肠癌和 直肠癌的发 ...

北京安贞医院作为北京市政府指定的首家"机器人+医疗"应用示范单位，现已有25款医疗机器人在临床 试用，覆盖了门诊、药房、病房、手术室、导管室等多个区域。机器人"员工"作为医生的智慧助手，正 成为北京安贞医院智慧化转型升级的力量。 （来源：工人日报） 2月3日，北京安贞医院通州院区库发核一体化智慧药房。 新华社记者 李欣 摄 ...

Investment Rating - The report indicates a positive outlook for the pharmaceutical sector, particularly for innovative drugs and companies expected to reach profitability in 2025 [1][9][15]. Core Insights - The innovative drug sector is anticipated to see significant growth due to the commercialization of core products and contributions from business development (BD) revenues, with companies like BeiGene, Innovent Biologics, and others expected to achieve profitability [1][9]. - The Pharma sub-sector is projected to experience a revenue growth rate of 15-20% in 2025, with notable companies such as Hansoh Pharmaceutical and China Biologic Products leading this growth [2][10]. - The CXO sector is also expected to report strong performance, with companies like WuXi AppTec forecasting substantial revenue and profit increases [3][11]. - The medical services sector is currently valued at historical lows, with a projected revenue growth of 13% for Genscript Biotech, highlighting the importance of monitoring industry changes [4][12]. Summary by Sections Innovative Drugs - Companies expected to achieve profitability in 2025 include BeiGene, Innovent Biologics, and others, driven by increased commercialization and BD revenues [1][9]. Pharma - Revenue growth of 15-20% is expected for leading companies such as Hansoh Pharmaceutical and China Biologic Products, with a significant boost anticipated for 3SBio due to a major BD deal with Pfizer [2][10]. CXO - WuXi AppTec is projected to achieve approximately 454.56 billion RMB in revenue, reflecting a year-on-year growth of about 15.84%, with adjusted net profits expected to rise significantly [3][11]. Medical Services - Genscript Biotech is expected to see a revenue increase of 13% in 2025, emphasizing the need to focus on overseas business expansion and AI integration in traditional medicine [4][12].

Group 1: IPO Overview - Zhuozheng Medical Holdings Limited (Zhuozheng Medical) was listed on the Hong Kong Stock Exchange on February 6, 2026, under the stock code "2677" [3] - The IPO raised a total of HKD 284 million by issuing 4,750,000 shares, with a subscription rate of 2730.73 times for the Hong Kong public offering and 5.79 times for the international offering [3] - Zhuozheng Medical's cornerstone investors include notable figures and companies such as He Xiaopeng, CEO of Xiaopeng Motors, and leading firms in the AI sector [4] Group 2: Company Performance - Zhuozheng Medical focuses on the high-end medical service market, targeting affluent consumers who prefer personalized healthcare [4] - The company ranked first and second among private high-end comprehensive medical service institutions in China based on the number of cities covered and patient visits projected for 2024 [4] - Revenue figures for Zhuozheng Medical from 2022 to 2024 are as follows: CNY 473 million, CNY 690 million, and CNY 959 million, with a compound annual growth rate (CAGR) of 42.2% [4] - Gross profit for the same period was CNY 44 million, CNY 134 million, and CNY 226 million, with a CAGR of 126.7% [4] - The company achieved profitability in 2024, with an adjusted net profit of approximately CNY 10.45 million in the first eight months of 2025 [4] Group 3: North Star Life - North Star Life Technology Co., Ltd. (North Star Life) was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 5, 2026, under the stock code "688712.SH" [6] - North Star Life specializes in innovative medical devices for cardiovascular disease diagnosis and treatment, having launched 11 products and having 6 in development as of September 30, 2025 [6][8] - The company's core products include the IVUS system and FFR system, both of which are recognized as leading innovations in China [7] Group 4: LuKe Technology - LuKe Technology (Beijing) Co., Ltd. (LuKe Technology) submitted its prospectus for listing on the Hong Kong Stock Exchange on February 6, 2026 [10] - Established in 2014, LuKe Technology focuses on smart locks and home security solutions, leading the market in China with a 5.8% share in 2024 [11] - The company reported revenues of CNY 1.015 billion in 2023 and CNY 1.086 billion in 2024, with a projected increase in revenue for the first three quarters of 2025 [11] Group 5: Tianyi Space Technology - Tianyi Space Technology Co., Ltd. (Tianyi Research Institute) signed a counseling agreement to initiate its A-share IPO process on January 27, 2026 [14] - The company has successfully launched 38 satellites, filling a gap in China's commercial SAR satellite market [15] - Tianyi's services include high-quality SAR data for various applications, contributing to disaster prevention and infrastructure monitoring [15] Group 6: BoRuiKang Technology - BoRuiKang Technology (Shanghai) Co., Ltd. (BoRuiKang) initiated its IPO process on the Sci-Tech Innovation Board on February 4, 2026 [18] - The company specializes in brain-machine interface technology and has successfully conducted surgeries using its product, NEO, in multiple hospitals [19] - BoRuiKang has received significant investments from various venture capital firms and aims to enhance its product capabilities in future iterations [19]

中国青年报客户端讯（刘心悦 中青报·中青网记者 林洁）近日，一场"改变IBD"沙龙在广东省广州市举 行。活动围绕炎症性肠病（IBD）的长期管理、医患沟通与生态建设等议题展开研讨，推动医患协同应 对疾病。 炎症性肠病（IBD）是一种可累及全消化道的慢性非特异性肠道炎症性疾病，主要包括克罗恩病 （CD）和溃疡性结肠炎（UC)，通常以反复发作的腹泻、腹痛、便血为主要特征，严重影响患者的身 体健康，给患者日常生活带来长期且沉重的负担，目前尚无法治愈。 许多IBD患者选择向同学、同事乃至亲密家人隐瞒病情，在孤立无援中独自承受身心双重的压力。现 场，患者小傅（化名）分享了从延误治疗到主动参与决策、最终重返职场的经历。小杏（化名）讲述了 在医生精准干预下，平衡疾病管理与高考、从容面对手术的故事，体现了医患坦诚沟通对诊疗进程的积 极推动作用。 与会3位医生指出，IBD诊疗既要追求"医学最优解"，更要兼顾患者"生活可行解"。在长期管理中，需通 过深化医患信任与沟通，鼓励患者全程参与诊疗，同时推动医生综合聆听其生活、家庭、情感等多维需 求，制定真正个性化的治疗方案。 中山大学附属第六医院知识城院区消化内科、内镜中心科主任郅敏结合 ...

脑动极光公告，公司之间接全资附属公司脑动极光医学科技数智（澳门）有限公司已于近期与澳门镜湖 医院正式签署《脑健康数字AI技术服务合作协议》。双方将围绕认知障碍的数字筛查、评估、训练及 全程健康管理，在澳门地区建立长期战略合作关系，共同构建覆盖「医院－社区－家居」的全链条脑健 康服务新模式。 ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it will outperform the overall market [1]. Core Insights - The report highlights that the commercialization of innovative drugs, combined with licensing income, is expected to lead to profitability for several companies in 2025, including BeiGene, Innovent Biologics, and others [1][9]. - The Pharma sub-sector is projected to achieve a revenue growth rate of 15-20% in 2025 for companies like Hansoh Pharmaceutical and China Biologic Products, with a significant revenue increase expected for 3SBio due to a major business development deal with Pfizer [2][10]. - The CXO sector is also expected to show strong performance, with companies like WuXi AppTec forecasting a revenue increase of approximately 15.84% and a net profit growth of about 102.65% in 2025 [3][11]. - In the medical services sector, the report notes that valuations are at historical lows, with a projected revenue growth of 13% for GuoShengTang in 2025, emphasizing the importance of overseas business expansion and AI integration in traditional Chinese medicine [4][12]. Summary by Sections Innovative Drugs - The report anticipates that several innovative drug companies will reach profitability in 2025 due to increased commercialization and business development income [9][15]. Pharma - The Pharma sub-sector is expected to see a revenue growth of 15-20% in 2025 for key players, with 3SBio projected to achieve over 100% growth due to a significant partnership with Pfizer [2][10]. CXO - WuXi AppTec is expected to report a revenue of approximately 454.56 billion RMB in 2025, with a net profit growth of around 102.65% [3][11]. Medical Services - GuoShengTang is projected to have a revenue growth of 13% in 2025, with a focus on overseas acquisitions and AI applications in traditional medicine [4][12].

Investment Rating - The report maintains a "Buy" rating for the medical services industry, suggesting a positive outlook for investment opportunities in this sector [10][64]. Core Insights - The medical services sector has shown resilience, with a recent increase in the sector's PE ratio to 34.43X and PB ratio to 3.49X, indicating a positive trend in valuation metrics [4][29]. - The approval of internet medical first diagnosis trials in Beijing marks a significant regulatory breakthrough, potentially accelerating the online medical service process and providing new market opportunities for private medical institutions [5][62][63]. - The report highlights the importance of digital regulation and standardization in enhancing service capabilities for private medical institutions, particularly in consumer healthcare sectors like pediatrics and dermatology [5][62]. Summary by Sections Industry Performance - The pharmaceutical and biological sector increased by 0.14%, ranking 15th among 31 primary industries, outperforming the Shanghai Composite Index by 1.47 percentage points [2][12]. - The medical services sub-sector reported a 1.31% increase, closing at 6827.17 points, with a year-to-date performance of 41.41% [24][27]. Company Performance - Top-performing companies in the medical services sector include Meidisi (+18.0%), Tongce Medical (+8.1%), and Nuosige (+5.7%), while underperformers include Haoyuan Pharmaceutical (-6.2%) and Baicheng Pharmaceutical (-4.5%) [3][27]. Valuation Metrics - The medical services sector's PE ratio has increased by 0.56X from the previous week, while the PB ratio has risen by 0.06X, indicating a strengthening in market confidence [4][29]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO in the pharmaceutical outsourcing sector, as well as companies like WuXi AppTec and Haoyuan Pharmaceutical [10][64]. - It also recommends monitoring private medical service providers with compliance experience, such as Aier Eye Hospital, as they are expected to benefit from the evolving regulatory landscape [5][64].

今天上午，"中国胸外科术后疼痛管理专家共识启动大会暨成果转化战略合作签约仪式"在上海市肺科医 院举行，大会聚焦胸外科术后引流与精准镇痛一体化技术，为相关创新成果推广奠定基础。 无需高频使用镇痛泵 为验证技术疗效，团队牵头在院内开展随机对照研究（IIT研究），初步结果显示，与使用常规引流管 的对照组相比，观察组患者术后疼痛控制与康复质量均显著提升。疼痛管理方面，观察组患者术后24小 时、48小时静息及咳嗽状态下的疼痛视觉模拟评分（VAS）大幅降低，其中术后24小时疼痛强度平均降 幅达18%，有效缓解了患者核心不适；康复进程方面，观察组患者术后48小时、72小时康复质量评分 （QoR-15）明显提高，为早期活动、肺功能恢复奠定基础，契合快速康复外科（ERAS）理念。 目前，该技术已应用于临床，让众多患者直接受益。患者反馈，术后疼痛可快速缓解，无需高频使用镇 痛泵，减轻了治疗负担；集成化装置贴合人体生理结构，患者耐受性良好，无明显局部不适或异物感。 这种"引流+镇痛"一站式方案，不仅降低了术后并发症发生率，还缩短了康复周期，显著提升了患者治 疗舒适度与安全感。 该原创技术已形成完整的临床研发与产业化落地体系，核心设 ...

新院区将成为"智慧医院"。其中，诊前智能导诊、精准分诊，可缩短患者候诊时间；院内智能导航可指 引就诊路线；AI预问诊自动梳理患者病情信息，提升医生诊疗效率。智能随访、互联网诊疗、药品配 送等服务也将陆续开通。 新院区计划优化患者、医护、物资流线，采取"一站式"就医布局。挂号、检查、缴费、取药集中设置， 医技科室紧邻诊区，减少患者往返奔波；急诊与手术室开通专用通道，确保急危重症救治高效衔接；智 能物流系统实现药品、耗材快速传输。院区将设置适老化设施、无障碍通道、家庭化产房。 新院区建设即将进入二次结构、机电安装、装饰装修施工阶段，预计2027年具备运营条件。 来源：北京日报客户端 2月8日，北京大学人民医院雄安院区主体结构全面封顶，预计2027年具备运营条件。该院院长王俊表 示，新院区将与北京院区一体化管理、同质化服务，并将AI（人工智能）服务贯穿诊疗全流程。 人民医院雄安院区于2023年11月20日动工，占地114.6亩，总建筑面积25.57万平方米。"北京院区专家团 队将每周固定在雄安出诊、开展手术。"王俊介绍，该院将重点专科、专家团队、科研平台整体导入雄 安，实现资源同源、服务同质、管理同步。 新院区将依 ...